Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $264.21 which represents a slight increase of $2.15 or 0.82% from the prior close of $262.06. The stock opened at $261.97 and touched a ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Biomedicines ("Generate") today announced that Mike Nally, Chief Executive Officer, will provide an update on the company's ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

Shocking profiteering in healthcare system continues to harm patients nationwide. • The 2024 Shkreli Awards highlighted the 10 most egregious examples of healthcare profiteering and dysfunction, ...

Bio-Thera Solutions Inc. announced that it has partnered with Tabuk Pharmaceutical Manufacturing Company to commercialize BAT2206, ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

The health benefits of time-restricted eating go beyond weight loss and may be most prominent in patients already with ...

Drug discovery is a key area for AI, given the speed at which models trained on massive datasets can tackle a variety of tasks. Last year, Nvidia said it was doubling down on AI-powered drug discovery ...